中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

小肝癌立体定向放射治疗的效果及预后分析

李甜甜 孙静 王权 丁俊强 王佳 薛慧 张弢 段学章

引用本文:
Citation:

小肝癌立体定向放射治疗的效果及预后分析

DOI: 10.3969/j.issn.1001-5256.2018.08.022
基金项目: 

首都特色基金(Z151100004015002); 

详细信息
  • 中图分类号: R730.55;R735.7

Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors

Research funding: 

 

  • 摘要: 目的探讨小肝癌患者接受立体定向放射治疗的疗效、安全性以及影响预后的因素。方法回顾性分析2011年3月-2014年10月于解放军三〇二医院行立体定向放射治疗的64例小肝癌患者的临床资料。随访患者的肿瘤控制情况和治疗后不良反应。Kaplan-Meier法分析生存情况;log-rank检验和Cox比例风险模型分析影响生存的相关因素。结果共纳入64例患者72个病灶。随访460个月,中位随访时间44个月。44个病灶(61.1%)完全缓解,20个病灶(27.8%)部分缓解,5个病灶(6.9%)稳定,3个病灶(4.2%)进展。客观有效率88.9%,1、3、5年局部控制率分别为94.4%、88.1%、78.7%。1、3、5年累积生存率分别为95.3%、71.6%、55.9%;无进展生存率分别为62.3%、33.5%、10.8%。不良反应多为12级。1例患者出现了胆红素升高4级反应。另外,约1/4患者出现了3级白细胞和(或)血小板的降低,治疗后1年左右均恢复至基线水平。多因素分析显示,白蛋白-胆红素分级和肿瘤数目为影响立体定向放射治疗后小肝癌患者累积生存率的独...

     

  • [1]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.
    [2]BRUIX J, REIG M, SHERMAN M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J].Gastroenterology, 2016, 150 (4) :835.
    [3] ADLER JR, CHANG SD, MURPHY MJ, et al.The cyberknife:A frameless robotic system for radiosurgery[J].Stereotact Funct Neurosurg, 1997, 69 (1-4) :124-128.
    [4]MENG M, WANG H, ZENG X, et al.Stereotactic body radiation therapy:A novel treatment modality for inoperable hepatocellular carcinoma[J].Drug Discov Ther, 2015, 9 (5) :372-379.
    [5]JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al.Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach——the ALBI grade[J].J Clin Oncol, 2015, 33 (6) :550-558.
    [6]TOYODA H, LAI PB, O'BEIRNE J, et al.Long-term impact of liver function on curative therapy for hepatocellular carcinoma:Application of the ALBI grade[J].Br J Cancer, 2016, 114 (7) :744-750.
    [7]ZHANG T, SUN J, HE WP, et al.Clinical effect of Cyber Knife stereotactic radiosurgery in treatment of patients with small hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (4) :694-698. (in Chinese) 张弢, 孙静, 何卫平, 等.射波刀立体定向放射治疗小肝癌的临床效果[J].临床肝胆病杂志, 2017, 33 (4) :694-698.
    [8]LI H, SUN J, ZHANG T, et al.Effect of Cyber Knife radiosurgery on survival rate of patients with recurrent liver cancer after surgery[J].J Clin Hepatol, 2017, 33 (12) :2337-2341. (in Chinese) 李欢, 孙静, 张弢, 等.射波刀治疗复发性肝癌患者的效果及预后分析[J].临床肝胆病杂志, 2017, 33 (12) :2337-2341.
    [9]European Association For the Study of the Liver.EASL-EORTC Clinical Practice Guidelines:Management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (6) :908-943.
    [10]BENEDICT SH, YENICE KM, DAVID F, et al.Stereotactic body radiation therapy:The report of AAPM Task Group 101[J].Med Phys, 2010, 37 (8) :4078-4101.
    [11]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[C]//Seminars in Liver Disease.2010:52-60.
    [12]CHEN AP, SETSER A, ANADKAT MJ, et al.Grading dermatologic adverse events of cancer treatments:The common terminology criteria for adverse events version 4.0[J].J Am Acad Dermatol, 2012, 67 (5) :1025-1039.
    [13]KHOJA L, LORIGAN P, ZHOU C, et al.Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma[J].J Invest Dermatol, 2013, 133 (6) :1582-1590.
    [14]VEROUX M, GROSSO G, CORONA D, et al.Age is an important predictor of kidney transplantation outcome[J].Nephrol Dial Transplant, 2012, 27 (4) :1663-1671.
    [15]BLOMGREN H, LAX I, NASLUND I, et al.Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator.Clinical experience of the first thirty-one patients[J].Acta Oncol, 2009, 34 (6) :861-870.
    [16]TSAI CL, HSU FM, CHENG JC.How to improve therapeutic ratio in radiotherapy of HCC[J].Liver Cancer, 2016, 5 (3) :210-220.
    [17]BUJOLD A, MASSEY CA, KIM JJ, et al.Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J].J Clin Oncol, 2013, 31 (13) :1631-1639.
    [18]SHAO L, SHI YX, ZHU HX, et al.Clinical study of stereotactic radiotherapy combined with Kanglaite injection in the treatment of primary liver cancer[J].Chin J Med Offic, 2017, 45 (3) :313-315. (in Chinese) 邵亮, 施艳新, 朱慧心, 等.立体定向放射治疗联合康莱特注射液治疗原发性肝癌临床研究[J].临床军医杂志, 2017, 45 (3) :313-315.
    [19]SANUKI N, TAKEDA A, OKU Y, et al.Stereotactic body radiotherapy for small hepatocellular carcinoma:A retrospective outcome analysis in 185 patients[J].Acta Oncol, 2014, 53 (3) :399-404.
    [20]SU T, LIANG P, LU H, et al.Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients[J].J Surg Oncol, 2016, 113 (2) :181-187.
    [21]SCORSETTI M, COMITO T, COZZI L, et al.The challenge of inoperable hepatocellular carcinoma (HCC) :Results of a single-institutional experience on stereotactic body radiation therapy (SBRT) [J].J Cancer Res Clin Oncol, 2015, 141 (7) :1301-1309.
    [22]KANG JK, KIM MS, CHO CK, et al.Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage therapy after incomplete transarterial chemoembolization[J].Cancer, 2012, 118 (21) :5424-5431.
    [23]QI WX, FU S, ZHANG Q, et al.Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma:A systematic review and meta-analysis[J].Radiother Oncol, 2015, 114 (3) :289-295.
    [24]DAHIYA D, WU TJ, LEE CF, et al.Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients:A 20-year experience[J].Surgery, 2010, 147 (5) :676-685.
  • 加载中
计量
  • 文章访问数:  2042
  • HTML全文浏览量:  38
  • PDF下载量:  384
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-06-04
  • 出版日期:  2018-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回